Es gab 50 kürzliche Insider-Transaktionen für IDEAYA Biosciences, Inc. (IDYA), darunter 37 Käufe und 10 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $128.94M und die gesamten Insider-Verkäufe auf $1.89M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Stein Jeffrey, Beaupre Darrin, Hata Yujiro S. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — IDYA
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-03-02 |
Stein Jeffrey |
Director |
Informierter Kauf |
50,000 |
$32.96 |
$1.65M |
54,281 |
| 2026-01-30 |
Beaupre Darrin |
Chief Medical Officer |
RSU-Zuteilung |
175,000 |
$32.19 |
$5.63M |
175,000 |
| 2026-01-30 |
Hata Yujiro S |
President and CEO |
RSU-Zuteilung |
600,000 |
$32.19 |
$19.31M |
600,000 |
| 2026-01-30 |
Snyder Douglas B. |
SVP, General Counsel |
RSU-Zuteilung |
130,000 |
$32.19 |
$4.18M |
130,000 |
| 2026-01-30 |
White Michael Anthony |
Chief Scientific Officer |
RSU-Zuteilung |
190,000 |
$32.19 |
$6.12M |
190,000 |
| 2026-01-30 |
Ruiz Briseno Andres |
See Remarks |
RSU-Zuteilung |
80,000 |
$32.19 |
$2.58M |
80,000 |
| 2026-01-30 |
Dorman Stuart |
Chief Commercial Officer |
RSU-Zuteilung |
155,000 |
$32.19 |
$4.99M |
155,000 |
| 2026-01-30 |
Bleharski Joshua |
Chief Financial Officer |
RSU-Zuteilung |
170,000 |
$32.19 |
$5.47M |
170,000 |
| 2025-11-28 |
Snyder Douglas B. |
SVP, General Counsel |
RSU-Zuteilung |
1,041 |
$16.91 |
$17.6K |
2,080 |
| 2025-11-28 |
Ruiz Briseno Andres |
See Remarks |
RSU-Zuteilung |
1,253 |
$16.91 |
$21.18K |
26,466 |
| 2025-06-27 |
Bleharski Joshua |
Chief Financial Officer |
Unbekannt |
250,000 |
$20.05 |
$5.01M |
- |
| 2025-06-24 |
Yarno Wendy L |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Rosen Terry J |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Stein Jeffrey |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Mackey Catherine J |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Morrison Scott W |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-06-24 |
Hampton Malcolm Garret |
Director |
RSU-Zuteilung |
20,000 |
$21.78 |
$435.6K |
20,000 |
| 2025-05-30 |
Snyder Douglas B. |
SVP, General Counsel |
RSU-Zuteilung |
1,039 |
$16.91 |
$17.57K |
1,039 |
| 2025-02-27 |
Beaupre Darrin |
Chief Medical Officer |
RSU-Zuteilung |
185,000 |
$20.24 |
$3.74M |
185,000 |
| 2025-02-27 |
Hata Yujiro S |
President and CEO |
RSU-Zuteilung |
600,000 |
$20.24 |
$12.14M |
600,000 |
| 2025-02-27 |
Snyder Douglas B. |
SVP, General Counsel |
RSU-Zuteilung |
33,000 |
$20.24 |
$667.92K |
33,000 |
| 2025-02-27 |
White Michael Anthony |
Chief Scientific Officer |
RSU-Zuteilung |
185,000 |
$20.24 |
$3.74M |
185,000 |
| 2025-02-27 |
Ruiz Briseno Andres |
See Remarks |
RSU-Zuteilung |
75,000 |
$20.24 |
$1.52M |
75,000 |
| 2025-02-27 |
Dorman Stuart |
Chief Commercial Officer |
RSU-Zuteilung |
15,000 |
$20.24 |
$303.6K |
15,000 |
| 2025-02-18 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
12,808 |
$19.52 |
$250.01K |
182,192 |
| 2024-12-11 |
Dorman Stuart |
Chief Commercial Officer |
Unbekannt |
170,000 |
$27.45 |
$4.67M |
- |
| 2024-11-29 |
Ruiz Briseno Andres |
See Remarks |
RSU-Zuteilung |
682 |
$23.26 |
$15.86K |
25,213 |
| 2024-09-26 |
Snyder Douglas B. |
SVP, General Counsel |
RSU-Zuteilung |
140,000 |
$30.50 |
$4.27M |
140,000 |
| 2024-09-18 |
Snyder Douglas B. |
Officer |
Unbekannt |
- |
- |
- |
- |
| 2024-06-27 |
Throne Jason |
Chief Legal Officer |
Optionsausübung (Verkauf) |
47,060 |
$7.01 |
$329.89K |
1,360 |
| 2024-05-31 |
Yarno Wendy L |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Rosen Terry J |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Stein Jeffrey |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Kelley Susan L. |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Mackey Catherine J |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Morrison Scott W |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-31 |
Hampton Malcolm Garret |
Director |
RSU-Zuteilung |
16,200 |
$36.55 |
$592.11K |
16,200 |
| 2024-05-29 |
White Michael Anthony |
Chief Scientific Officer |
Informierter Verkauf |
851 |
$36.78 |
$31.3K |
- |
| 2024-05-16 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
34,433 |
$4.31 |
$148.41K |
49,454 |
| 2024-05-15 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
83,856 |
$4.31 |
$361.42K |
83,887 |
| 2024-05-14 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
56,711 |
$4.31 |
$244.42K |
167,743 |
| 2024-03-01 |
Beaupre Darrin |
Chief Medical Officer |
RSU-Zuteilung |
160,000 |
$46.22 |
$7.4M |
160,000 |
| 2024-03-01 |
Hata Yujiro S |
President and CEO |
RSU-Zuteilung |
480,000 |
$46.22 |
$22.19M |
480,000 |
| 2024-03-01 |
Throne Jason |
Chief Legal Officer |
RSU-Zuteilung |
125,500 |
$46.22 |
$5.8M |
125,500 |
| 2024-03-01 |
White Michael Anthony |
Chief Scientific Officer |
RSU-Zuteilung |
140,000 |
$46.22 |
$6.47M |
140,000 |
| 2024-03-01 |
Ruiz Briseno Andres |
See Remarks |
RSU-Zuteilung |
85,000 |
$46.22 |
$3.93M |
85,000 |
| 2024-02-09 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
23,557 |
$4.31 |
$101.53K |
224,454 |
| 2024-02-09 |
Ruiz Briseno Andres |
See Remarks |
Informierter Verkauf |
2,000 |
$46.02 |
$92.04K |
24,531 |
| 2024-02-08 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
75,815 |
$4.31 |
$326.76K |
248,011 |
| 2024-02-01 |
Hata Yujiro S |
President and CEO |
Optionsausübung (Verkauf) |
628 |
$4.31 |
$2.71K |
323,826 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
